Autolus Therapeutics PLC Sponsored ADR

AUTL Healthcare Biotechnology

In the quarter to June 2026, revenue grew 118.4%, EPS grew 16.7% and free cash flow grew 67.6%, each against the same quarter a year earlier.

1.63 0.11 −6.32%
Market cap
$463.1M
P/E
0.0×
Fwd P/E
−1.7×
Dividend yield
—
F-score
3/9
Altman Z
−3.17
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

— 2 3 —
ROE
(60.56%) (94.98%) (120.42%) (133.00%)
ROA
(30.19%) (41.92%) (45.38%) (46.15%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(45.11%) (67.49%) (78.71%) (85.46%)
Average Days of Receivables
232.76 116.32 109.01 138.03
Free Cash Flow per Share
(1.15) (1.22) (1.08) (0.87)
Free Cash Flow
(306.77) (323.77) (286.81) (232.73)
Capital Expenditures
(52.59) (40.20) (13.49) (7.12)
Other line items
Cash ROIC
(48.36%) (59.17%) (84.42%) (65.43%)
Accounts Receivable Turnover
1.37 6.27 4.41 3.31
Accounts Payable Turnover
11.69 38.15 32.54 29.23
Inventory Turnover
0.00 5.16 4.30 3.45
Average Days of Payables
55.28 11.68 6.63 5.04
Days of Inventory on Hand
139.73 125.78 117.78 123.24
Tax Rate
0.02 0.01 0.00 0.00
Research and Development Expense of Revenue
220.79% 156.11% 121.10% 95.95%
Selling, General and Administrative Expense of Revenue
255.04% 174.93% 153.62% 130.49%
Share Based Compensation of Revenue
33.70% 19.15% 16.34% 13.15%
Interest Coverage
16.11 (7.38) (7.03) (5.92)
Operating CF/Net income
1.13 0.99 0.95 0.81
Depreciation/Fixed assets
0.14 0.15 0.17 0.17
Capex/Depreciation
(5.68) (4.10) (1.32) (0.68)
Revenue per Share
0.19 0.28 0.35 0.44
Operating CF per Share
(0.96) (1.07) (1.03) (0.85)
Capex per Share
(0.20) (0.15) (0.05) (0.03)
Capex to Sales
1.03 0.53 0.15 0.06

Fold the line items

Columns are period end dates · fundamentals updated 28 Sep 2026